Xenomics Inc. (XNOM) Executes Research Contract With North Shore-LIJ Health Sys. To Begin Human Clinical Studies Of Non-Invasive Prenatal DNA Tests
10/19/2005 5:10:23 PM
NEW YORK--(BUSINESS WIRE)--May 9, 2005--Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, has executed a contract with North Shore-Long Island Jewish (LIJ) Health System, one of the nation's largest healthcare institutions, to begin conducting human clinical studies in the next development phase of the Company's revolutionary Transrenal-DNA (Tr-DNA) technology. The study will test the technology's ability to non-invasively detect Down syndrome in unborn babies using a safe and simple urine collection from the mother.
Under the research agreement, which is subject to institutional review board approval, Xenomics and North Shore-LIJ will collaborate to begin human clinical studies of the Company's safe, inexpensive and non-invasive medical tests to detect Down syndrome, a serious genetic abnormality, in unborn children. North Shore-LIJ, a 14-hospital network serving Long Island, Queens and Staten Island that treats a large population of high-risk pregnancy patients, will provide Xenomics scientists with anonymous urine samples from expectant mothers carrying children identified with Down syndrome. This will enable Xenomics to conduct the next phase of clinical studies as it develops its technology for the diagnostic marketplace.
comments powered by